BRIEF—Genevant Sciences appoints Bo Rode Hansen as CEO

Genevant Sciences has appointed Bo Rode Hansen, the former global head of RNA therapeutics at Roche, as president and chief executive officer.

Dr Hansen was also previously general manager of the Roche Innovation Center Copenhagen and was head of drug discovery at Santaris Pharma.

“I am honored to serve and lead this exceptional team,” Dr Hansen said. “Genevant is well positioned to succeed as the first modality-agnostic RNA therapeutics company. We believe RNA therapeutics will expand the horizon of druggable targets, permitting us to develop treatments for a range of disorders with high unmet need. Our holistic approach is truly differentiated and allows us to fully maximize the potential of these therapeutics.”